# Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma

> **NCT02297958** · — · COMPLETED · sponsor: **Rennes University Hospital** · enrollment: 28 (actual)

## Conditions studied

- Ovarian Carcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02297958
- **Lead sponsor:** Rennes University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-15
- **Primary completion:** 2019-07-27
- **Final completion:** 2019-07-27
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2020-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02297958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02297958, "Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02297958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*